PHARMA
GHIT Fund Secures US$200 Million For Second Phase
The Government of Japan will contribute roughly half of the US$200 million replenishment, with the remainder provided by partners including the Bill & Melinda Gates Foundation.
One Biomed & A*STAR Create Lab For Molecular Diagnostic Assays
One Biomed and A*STAR have established a joint laboratory to develop a molecular diagnostic platform for infectious diseases in Asia.
Extending The Range Of Diseases Covered By A Rice-Based Vaccine
Astellas and the Institute of Medical Science at the University of Tokyo are expanding the range of diseases that can be covered by their rice-based oral vaccine, MucoRice.
WuXi NextCODE Raises US$75 Million In Series B Financing
WuXi NextCODE has raised US$75 million from investors including Temasek and Yunfeng Capital to roll out their genomic data platform across China and beyond.
CBMG & GE Healthcare Life Sciences Collaborate On Cancer Immunotherapy
CMBG and GE Healthcare Life Sciences China have entered a strategic colllaboration to develop industrial control processes in CAR-T and stem cell manufacturing.
ChemChina’s Syngenta Acquisition Approved
China’s state-owned agrochemical company ChemChina has been cleared to acquire Syngenta, a Swiss agriculture research company.
Wanda Group Invests US$10 Billion In Chengdu Healthcare Park
In partnership with the Chengdu Municipal Government, Wanda Group will invest US$10 billion to establish a healthcare industry park in Chengdu, China.
CBMG Expands CAR-T And Stem Cell Facilities
Cellular Biomedicine Group has expanded its facility in Huishan High Tech Park to increase the company's capacity for CAR-T and stem cell products.
Promising Results For Takeda’s Dengue Vaccine
Takeda's dengue vaccine has proven to be safe and able to produce an antibody response against all four serotypes of dengue in an interim analysis of their ongoing Phase 2 trial.
